Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Reuter

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The European Respiratory Journal|May 5, 2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South AfricaErika Mohr, Jennifer Hughes, Anja Reuter, et al.
Journal of Clinical Microbiology|February 16, 2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort StudyHelen Cox, Galo A Goig, Zubeida Salaam-Dreyer, et al.
The New England Journal of Medicine|May 30, 2019
Bedaquiline Microheteroresistance after Cessation of Tuberculosis TreatmentMargaretha de Vos, Serej D Ley, Kristin B Wiggins, et al.
The Lancet. Microbe|November 12, 2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology studyHelen Cox, Zubeida Salaam-Dreyer, Galo A Goig, et al.
The Lancet. Microbe|November 6, 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyBrigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, et al.
The Lancet. Infectious Diseases|November 15, 2021
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyNazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The European Respiratory Journal|May 5, 2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South AfricaErika Mohr, Jennifer Hughes, Anja Reuter, et al.
Journal of Clinical Microbiology|February 16, 2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort StudyHelen Cox, Galo A Goig, Zubeida Salaam-Dreyer, et al.
The New England Journal of Medicine|May 30, 2019
Bedaquiline Microheteroresistance after Cessation of Tuberculosis TreatmentMargaretha de Vos, Serej D Ley, Kristin B Wiggins, et al.
The Lancet. Microbe|November 12, 2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology studyHelen Cox, Zubeida Salaam-Dreyer, Galo A Goig, et al.
The Lancet. Microbe|November 6, 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyBrigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, et al.
The Lancet. Infectious Diseases|November 15, 2021
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyNazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Pageof 4